GC061 HIV Positive: HIV Related Diseases, Accidental Needle Prick Injury
HIV-related diseases are opportunistic infections and malignancies arising from immunodeficiency caused by HIV, while accidental needle prick injury is a percutaneous exposure to potentially infected blood or body fluids requiring immediate post-exposure prophylaxis assessment.
HIV Positive: HIV-Related Diseases & Accidental Needle Prick Injury
This lecture, delivered by Dr. Jacky Chan (Consultant, Princess Margaret Hospital / HA Infectious Disease Centre), covers the full clinical spectrum of HIV medicine from a generalist's perspective: virology, epidemiology (global and Hong Kong), clinical presentation across all phases, diagnosis (including the window period), AIDS-defining illnesses, opportunistic infections (with case-based teaching), antiretroviral therapy, and — critically for every doctor — prevention strategies including post-exposure prophylaxis (PEP) after needlestick injury. [1]
Why this matters for every specialty: The lecture opens with the point that no matter which specialty you pursue, you will encounter HIV-infected patients. It then illustrates this with examples across family medicine, dermatology, obstetrics, ophthalmology, and cardiology. [1]
Learning Objectives (derived from slides):
- Understand HIV virology and natural history
- Know the current epidemiological situation in Hong Kong
- Recognise acute HIV seroconversion and AIDS-defining conditions
- Diagnose HIV using the two-step testing algorithm
- Understand HAART: classes, goals, paradigm shift
- Know prevention strategies: PrEP, PEP, safe sex, MTCT prevention
- Manage accidental needlestick injury — the practical drill every HKU medical student must know
Core Concepts & Mechanisms
HIV is a retrovirus. There are two types: HIV-1 (responsible for the global pandemic) and HIV-2 (limited primarily to West Africa). [1]
High Yield — HIV Replication Cycle
The replication cycle is the basis for understanding every drug class. Examiners love asking "which step does Drug X target?"
Replication steps (directly from slides) [1]:
- HIV enters the host most often through anogenital mucosa
- HIV enters CD4+ T lymphocytes through binding of viral glycoproteins (gp120/gp41) to the CD4 receptor + a co-receptor (CCR5 or CXCR4)
- Intracellularly, reverse transcriptase transcribes the RNA genome to DNA
- Integration of HIV DNA into the host genome (by integrase)
- HIV matures by proteases releasing individual HIV proteins
Why this matters: Each step is a drug target:
- Entry/fusion → fusion inhibitors, CCR5 antagonists
- Reverse transcription → NRTIs, NNRTIs
- Integration → INSTIs (integrase strand transfer inhibitors)
- Protease cleavage → PIs
HIV causes immune destruction through CD4 T-cell depletion. The outcomes of immune dysfunction are infections and malignancy. [1]
Why CD4 depletion matters: CD4+ T-helper cells orchestrate the adaptive immune response. As CD4 counts fall, the patient becomes progressively vulnerable to opportunistic infections (OIs) in a predictable, CD4-count-dependent hierarchy. This is the conceptual backbone of the entire lecture.
Three phases [1]:
| Phase | Description | Duration |
|---|---|---|
| Acute infection | High viremia, mono-like illness, very infectious | 2-4 weeks post-exposure |
| Asymptomatic (clinical latency) | Gradual CD4 decline, patient feels well | Years (median ~10 years without treatment) |
| AIDS (symptomatic phase) | OIs, cancers, wasting | Median survival ~20 months without ART |
Without treatment, about half of infected people will progress to AIDS in 10 years. [1]
HIV incidence in Hong Kong: the lecture poses "increasing or decreasing?" — The answer, per CHP data and lecture framing, is that incidence was increasing (peaked ~2015), with a subsequent downtrend. [1][2]
Most likely route of HIV transmission in HK: MSM (men who have sex with men) — This is the correct answer per the lecture slides. [1]
- Cumulative incidence ~11,500 (as of ~2022)
- Annual new cases ~450 at peak, trending down after the START trial era
- HIV clinic services in HK: Princess Margaret Hospital (HA), Queen Elizabeth Hospital (HA), Kowloon Bay Integrated Centre (DH)
- 90-90-90 target: 90% aware of status → of those, 90% on ART → of those, 90% virally suppressed
Exam Framing
The lecture explicitly asks "Is HIV a terminal illness, chronic illness, or curable illness?" — The intended answer is chronic illness (with effective ART). It is NOT curable (no eradication of integrated proviral DNA), but it IS manageable as a chronic disease. [1]
Clinical Presentation & Early Identification
Clinical scenario: M/40, lorry driver. 1 week of fever, myalgia, malaise, faint rash over trunk and limbs. Examination: shotty cervical lymph nodes, maculopapular non-itchy rash. [1]
Investigations: NPA flu/COVID negative, WCC 5.6 with atypical lymphocytes, Monospot positive. History reviewed → commercial sex in China. [1]
Anti-HIV Ab: indeterminate. HIV RNA: positive. → Impression: Acute seroconversion of HIV [1]
Acute HIV infection (acute retroviral syndrome) key teaching points from the slide [1]:
- Usual onset 2-4 weeks after exposure
- Mononucleosis-like illness in 50-60%: fever, pharyngitis, lymphadenopathy, rash, headache
- Lasts 10-15 days
- Lab: mild anaemia, thrombocytopenia, raised ALT, atypical lymphocytes
- Clinical implications:
- Need to repeat HIV antibody test if first test negative (window period)
- Initiation of ART recommended for confirmed infection
- Prevention of transmission (patient is highly infectious during acute phase due to massive viremia)
Why Monospot Can Be Misleading
Acute HIV seroconversion mimics infectious mononucleosis. A positive Monospot (heterophile antibody) does NOT exclude concurrent/alternative diagnoses. If there are risk factors for HIV (e.g., commercial sex), always check HIV serology AND consider HIV RNA if in the window period. The lecture deliberately shows this trap. [1]
These are conditions that should prompt an HIV test [1]:
- Unexplained generalised lymphadenopathy
- Unexplained weight loss
- Idiopathic thrombocytopenia
- Herpes zoster (especially in young patients)
- Oral candidiasis
- Severe bacterial infections (e.g., invasive pneumococcal disease)
"Offer HIV test when you encounter these conditions" — direct slide quote. [1]
This is extremely high-yield for exams. The lecture includes a table/figure correlating CD4 thresholds with specific OIs [1][2]:
| CD4 Count (cells/mm³) | Opportunistic Infections / Conditions |
|---|---|
| > 500 | Generally well; may have generalized lymphadenopathy |
| 200-500 | Oral candidiasis, pulmonary TB, herpes zoster/chickenpox, Kaposi's sarcoma |
| < 200 | PCP (Pneumocystis jirovecii pneumonia), extrapulmonary TB |
| < 100 | Oesophageal candidiasis, cryptococcosis, penicilliosis/talaromycosis, toxoplasmosis |
| < 50 | CMV retinitis, disseminated MAC (Mycobacterium avium complex) |
High Yield — CD4 Thresholds
Memorise this table. It is tested repeatedly in MCQs and SAQs. The key discriminator: PCP occurs at CD4 < 200, while CMV and MAC occur at CD4 < 50. Penicilliosis/talaromycosis occurs at CD4 < 100.
Diagnosis of HIV Infection
2-step testing: Screening → Confirmatory [1]
| Step | Test | Characteristics |
|---|---|---|
| Screening | 4th generation HIV-1/2 Ag (p24)/Ab combination immunoassay (ELISA) | Highly sensitive; window period ~14-21 days |
| Confirmatory | Western Blot assay (detects Ab against specific viral proteins) OR HIV-1/HIV-2 antibody differentiation immunoassay | Highly specific |
| If WB negative/indeterminate | HIV RNA PCR | Detects virus directly; window period ~10 days; used for seroconverting patients and neonates |
High Yield — The Window Period
The window period is the time between infection and when a test becomes positive. [1]
- Nucleic acid test (NAT/RNA PCR): ~10 days — used for blood donor screening and neonates
- Combo assay (4th gen ELISA: p24 + HIV Ab): ~14-21 days
- Antibody-only tests: longer window (~3-4 weeks)
During the window period, a patient can be infectious but test negative on antibody-based tests. This is why HIV RNA PCR is essential for diagnosing acute seroconversion (as in Case 1).
Rapid HIV testing is available (e.g., point-of-care tests at CHP sites). [1]
The lecture references Sullivan et al. (PLoS One 2013) — certain indicator conditions (e.g., TB, lymphoma, HBV/HCV, recurrent pneumonia, unexplained leukocytopenia, STIs) should prompt routine HIV testing regardless of perceived risk. [1]
Case-Based Opportunistic Infections
Scenario: M/35 with history of herpes zoster at age 28. 1 month low-grade fever, dry cough, decreased exercise tolerance, SOB on exertion. TOCC negative. [1]
CXR: Diffuse bilateral symmetrical interstitial infiltrates from hila (ground-glass pattern on CT). [1]
Investigations: WCC 2.1, lymphocyte 0.3, CRP 9.8, sputum C/ST commensals, AFB smear negative. Given Augmentin + azithromycin → persistent fever, oxygen desaturation. [1]
Sputum induction → Pneumocystis jirovecii present. Anti-HIV positive. CD4: 45. [1]
PCP key facts [1]:
- Caused by Pneumocystis jirovecii, classified as fungus but shares biologic characteristics with protozoa
- 90% of cases occur when CD4 < 200 cells/mm³
- Clinical triad: chronic dry cough, SOB on exertion, fever
- CXR: diffuse, bilateral, symmetrical interstitial infiltrates from hila
- Diagnosis: sputum induction or bronchoscopy → histology staining
- Treatment: High-dose co-trimoxazole (septrin) ± steroid if severe (PaO₂ < 70 mmHg or A-a gradient > 35)
Why Steroids in Severe PCP?
Steroids (prednisolone) are added in severe PCP because the inflammatory response to dying organisms can worsen gas exchange. Steroids reduce this inflammation and improve survival. This is one of the few infectious situations where steroids are beneficial. [1]
Scenario: M/58, HT/DM, 1 month dysphagia, no vomiting, weight loss. WCC 4.5, lymphocyte 0.5. [1]
OGD: Generalized whitish plaque-like lesions over oesophagus → biopsy: Candida. Oral thrush also present. [1]
History reviewed: prostitute visits in Shenzhen ~10 years ago. Anti-HIV positive, CD4: 85. [1]
Treatment: oral fluconazole + HAART [1]
Why this matters: Oesophageal candidiasis is an AIDS-defining illness (unlike oral candidiasis, which is Category B). It typically occurs at CD4 < 100. The presence of oral thrush + dysphagia in an at-risk patient should trigger HIV testing.
Scenario: M/36, Thai, 4 years in HK. 2 months of generalised non-itchy skin rash, fever, weight loss. [1]
Examination: Febrile, cervical and groin lymph nodes, erythematous papules over 4 limbs and face, some being 'umbilicated', liver edge palpable. [1]
Blood culture: Penicillium marneffei (now Talaromyces marneffei). Ex-IVDA, known HIV from Bangkok 6 years ago, defaulted follow-up. [1]
Penicilliosis/Talaromycosis key facts [1]:
- Caused by dimorphic fungus Talaromyces marneffei (formerly Penicillium marneffei)
- Endemic in Southeast Asia (especially Northern Thailand and Vietnam) and southern China
- Clinical triad: fever, anaemia, weight loss
- Pathognomonic sign: generalised skin papules with central umbilication resembling molluscum contagiosum
- Diagnosis: blood fungal culture, bone marrow culture
- Treatment: IV amphotericin B for 2 weeks → long-term oral itraconazole
- CD4 at presentation in this case: 14
High Yield — Umbilicated Papules in HIV
If you see "umbilicated skin papules" + "Southeast Asian origin" + "advanced HIV" in an MCQ stem, the answer is almost certainly talaromycosis (penicilliosis). This was tested in the 2022 MCQ (Q19). [3]
Management of HIV Infection
At entry into care [1]:
- CD4 T-cell count
- Plasma HIV RNA (viral load)
- CBC, chemistry profile, ALT, BUN, creatinine, urinalysis
- Serologies for hepatitis A, B, and C
- Fasting blood glucose and serum lipids
- Genotypic resistance testing
Why each matters:
- CD4 + viral load = staging and treatment urgency
- Hep A/B/C = co-infection management (shared transmission routes); Hep B has overlapping NRTI therapy (tenofovir, lamivudine)
- Glucose/lipids = ART side effects (metabolic syndrome) and cardiovascular risk
- Resistance testing = guides initial regimen choice
HAART = Highly Active Antiretroviral Therapy [1]
Six drug classes [1]:
| Class | Abbreviation | Mechanism | Key Drugs (from slides) |
|---|---|---|---|
| NRTIs | Nucleoside reverse transcriptase inhibitors | Incorporated into viral DNA → chain termination | Tenofovir (TDF/TAF), emtricitabine (FTC), lamivudine (3TC), abacavir (ABC), zidovudine (AZT) |
| NNRTIs | Non-nucleoside RTIs | Bind directly to RT → conformational change | Efavirenz (EFV), rilpivirine (RPV) |
| PIs | Protease inhibitors | Block protease → immature non-infectious virions | Saquinavir, ritonavir (booster) |
| INSTIs | Integrase strand transfer inhibitors | Block integration of viral DNA into host genome | Dolutegravir (DTG), raltegravir (RAL), elvitegravir (EVG), bictegravir (BIC) |
| Fusion inhibitors | Block viral-cell membrane fusion | Enfuvirtide | |
| CCR5 antagonists | Block CCR5 co-receptor | Maraviroc |
The lecture walks through the evolution from 1981 (AIDS first reported) to modern single-tablet regimens [1]:
| Year | Milestone |
|---|---|
| 1981 | AIDS first reported |
| 1984 | HIV identified |
| 1987 | Zidovudine (AZT) first approved |
| 1995 | First PI (saquinavir) |
| 1996 | Ritonavir (booster); combination ART era begins |
| 1998 | Two NRTI + potent third agent |
| 2006 | First single-tablet regimen (EFV/TDF/FTC) |
| 2018 | Bictegravir/TAF/FTC (modern INSTI-based STR) |
The paradigm shift: Potent ART → Less side effects → Simplified → Less frequent drug administration [1]
Pill burden evolution [1]:
- 1996: 10 pills, 3× daily
- 2006: 1 pill, 1× daily
Five goals [1]:
- Maximally suppress plasma HIV viral load
- Restore and preserve immunological function
- Reduce HIV-related morbidity and mortality
- Improve quality of life
- Prevent vertical transmission in women of childbearing potential
U=U: When a person living with HIV achieves and maintains an undetectable viral load through ART, they cannot sexually transmit HIV. This is a landmark public health message and reduces stigma. [1]
DHHS recommended initial regimens (from slides) — INSTI-based regimens are now preferred [1]:
- Bictegravir/TAF/FTC (single tablet)
- Dolutegravir/ABC/3TC (single tablet; requires HLA-B*5701 negative)
- Dolutegravir + TAF/FTC
Two-drug regimens (2DR) are now also recommended for select treatment-naïve individuals (e.g., DTG + 3TC). [1]
Injectable ART: Cabotegravir + rilpivirine IM every 2 months for virologically suppressed patients — a major advance in convenience and adherence. [1]
Prevention
Risk increases with [1]:
- Higher viremia
- Receptive anal intercourse (highest per-act risk)
- Presence of other STDs (especially genital ulcers)
Strategies [1]:
- Safe sex (condom use, avoid illicit drugs, limit concurrent partners)
- Male circumcision (reduces heterosexual female-to-male transmission)
- Treat other STDs
- ART for the HIV-positive partner (treatment as prevention / U=U)
- Pre-exposure prophylaxis (PrEP)
Without intervention: risk 15-40% [1]
- Transmission can occur in utero, intrapartum, and postpartum (breastfeeding)
Strategies [1]:
- HIV testing for all pregnant women (universal antenatal screening)
- Effective antenatal/intrapartum/postpartum ART
- Caesarean section (if viral load not suppressed)
- Avoid breastfeeding (in resource-rich settings)
PrEP = use of ARVs to prevent HIV acquisition in HIV-negative people at substantial risk [1]
Strategies [1]:
- Daily oral PrEP: TDF/3TC (or TDF/FTC)
- For receptive anal sex: effective after 7 days of daily use
- For other activities: effective after 21 days
- Event-driven PrEP (2+1+1): 2 pills 2-24 hours before sex → 1 pill 24h after → 1 pill 48h after
- IPERGAY trial: TDF-FTC before and after sexual activity provided 86% relative risk reduction in HIV acquisition among MSM [1]
- Injectable PrEP: IM cabotegravir every 2 months [4]
Accidental Needlestick Injury — Post-Exposure Prophylaxis (PEP)
This is one of the most practically important sections for any medical student or healthcare worker.
Transmission risk [1]:
- 0.33% following percutaneous exposure (needlestick/sharps injury)
- 0.09% following mucosal exposure
- 0% following intact skin exposure — intact skin is an effective barrier; contamination of intact skin is NOT considered an exposure
Infectious [1]:
- Blood, semen, vaginal secretions, other fluids contaminated with visible blood
- Potentially infectious (undetermined risk): CSF, synovial, pleural, peritoneal, pericardial, amniotic fluid
NOT considered infectious (unless blood-contaminated) [1]:
- Faeces, nasal secretions, saliva, gastric secretions, sputum, sweat, tears, urine, vomitus
High Yield — Saliva is NOT Infectious for HIV
A common MCQ trap: being spat on or bitten (without blood) by an HIV-positive patient does NOT constitute an HIV exposure. Saliva is NOT infectious for HIV unless visibly contaminated with blood.
Immediate steps [1]:
- Don't panic!
- Immediate cleansing of exposed site
- Skin: wash with soap and water
- Small wounds/punctures: cleanse with antiseptic (e.g., alcohol-based hand hygiene agent)
- Mucosal surface: flush with water
- Clinical documentation: details of the exposure, source patient status, recipient HCP details
[1]:
- Baseline HIV test immediately after exposure
- Follow-up testing: 6 weeks and 4 months (if 4th generation Ag/Ab test used)
- Also test for Hepatitis B and C
Preferred regimens [1]:
- Tenofovir-emtricitabine (Truvada) + dolutegravir 50mg QD
- Tenofovir-emtricitabine (Truvada) + raltegravir 400mg BD
- Tenofovir alafenamide-emtricitabine + bictegravir (single tablet)
Timing: goal is to start within 1-2 hours after exposure. PEP is less effective if > 72 hours. [1]
Duration: 28 days [1]
Starter kit available in AED [1]
Referred to staff clinic / regional post-exposure HIV clinic for follow-up [1]
PEP Indications
PEP should be offered to HCP with percutaneous, mucous membrane, or non-intact skin exposure to blood or bloody body fluids of a patient with known HIV infection, or while waiting HIV testing for unknown cases. [1]
Exam Intelligence
| Theme | Stem Style | Key Discriminators |
|---|---|---|
| Acute seroconversion | "M/30 with fever, rash, sore throat, atypical lymphocytes, recent unprotected sex — what diagnosis? What test?" | Anti-HIV Ab may be indeterminate → need HIV RNA PCR |
| PCP | "M/35, dry cough, SOB, bilateral interstitial infiltrates, CD4 45 — diagnosis and treatment?" | High-dose septrin ± prednisolone; sputum induction for diagnosis |
| Talaromycosis | "Southeast Asian patient, umbilicated skin papules, hepatosplenomegaly, CD4 14" | Blood fungal culture; Rx = amphotericin B → itraconazole |
| Needlestick PEP | "You sustain a needlestick from an HIV+ patient. What do you do?" | Wash → baseline test → PEP within 1-2h → Truvada + DTG × 28 days |
| CD4 thresholds | MCQ with CD4 value and OI options | PCP < 200; crypto/penicilliosis < 100; CMV/MAC < 50 |
| PrEP | "How would you counsel an MSM at high risk of HIV?" | Daily TDF/FTC or event-driven 2+1+1 |
| MTCT prevention | "HIV-positive pregnant woman — management?" | ART, C-section if needed, avoid breastfeeding |
| Window period | "Patient had exposure 10 days ago, ELISA negative — does this exclude HIV?" | No — within window period; repeat or use HIV RNA |
| Body fluids | "Which fluids are NOT infectious for HIV?" | Saliva, urine, sweat, tears (unless blood-contaminated) |
| Trap | Correct Approach |
|---|---|
| Confusing oral candidiasis (Category B, not AIDS-defining by itself) with oesophageal candidiasis (Category C, AIDS-defining) | Oesophageal involvement = AIDS-defining |
| Assuming a negative ELISA excludes HIV | Check timing relative to exposure; may be in window period |
| Thinking PEP must be started only if source is confirmed HIV+ | PEP should be offered while awaiting source testing for unknown cases |
| Forgetting steroid use in severe PCP | Add prednisolone if PaO₂ < 70 or A-a gradient > 35 |
| Listing saliva as an infectious HIV fluid | NOT infectious unless blood-contaminated |
| Confusing PrEP with PEP | PrEP = before exposure (ongoing prophylaxis); PEP = after exposure (28-day course) |
- HBV carrier lecture [7]: Tenofovir and lamivudine are NRTIs used in BOTH HIV and HBV. If a co-infected patient stops ART containing tenofovir, HBV may flare — always check HBV status before starting/stopping ART.
- Immunodeficiency lecture [8]: HIV is the most common acquired immunodeficiency; contrast with primary immunodeficiencies (SCID, CVID, etc.) which present differently.
- Infection in immunocompromised lecture [9]: The CD4-threshold approach to OIs in HIV parallels the neutrophil-count approach in chemotherapy patients.
- TB co-infection [10]: HIV + TB = bidirectional synergy. TB increases HIV viremia (TNF-α); HIV increases TB activation risk. Always screen for TB in HIV and vice versa.
Q1 (SAQ-style): A 32-year-old MSM presents with 1 week of fever, sore throat, maculopapular rash, and cervical lymphadenopathy. His HIV ELISA is "indeterminate." What further test would you order and why?
Model answer: HIV RNA PCR — the patient is likely in the window period of acute HIV seroconversion. During this phase, antibody levels are insufficient for a definitive ELISA result, but HIV RNA is already detectable (~10 days post-infection). A positive HIV RNA confirms acute infection.
Q2 (MCQ-style): Which of the following CD4 counts is MOST associated with PCP?
- A. < 500
- B. < 200 ✓
- C. < 100
- D. < 50
Q3 (SAQ-style): You sustain a needlestick injury from a hollow-bore needle used on an HIV-positive patient. Outline your immediate management.
Model answer: (1) Immediate wound care — wash with soap and water, apply antiseptic; (2) Baseline HIV test; (3) Start PEP within 1-2 hours — Truvada (TDF/FTC) + dolutegravir 50mg QD for 28 days; (4) Also test for HBV and HCV; (5) Follow-up HIV testing at 6 weeks and 4 months; (6) Refer to staff clinic/post-exposure HIV clinic.
Active Recall - HIV & Needlestick Injury
High Yield Summary
HIV is a retrovirus causing CD4 T-cell depletion → immunodeficiency → opportunistic infections and malignancies. Diagnose with 2-step testing (4th gen ELISA → Western Blot/RNA PCR). Acute seroconversion mimics mono — always check HIV RNA if ELISA is indeterminate and risk factors are present. CD4 thresholds predict OIs: PCP at < 200, cryptococcosis/talaromycosis at < 100, CMV/MAC at < 50. HAART (now INSTI-based single-tablet regimens) has transformed HIV into a chronic manageable disease (U=U). Prevention: condoms, PrEP (daily or event-driven TDF/FTC), MTCT strategies (ART + C-section + no breastfeeding). Needlestick PEP: wash immediately → baseline HIV test → start Truvada + dolutegravir within 1-2 hours → 28 days → follow-up at 6 weeks and 4 months. Percutaneous risk = 0.33%. Intact skin = no exposure. Saliva/urine/sweat are NOT infectious. MSM is the most common transmission route in HK.
[1] Lecture slides: GC 061. HIV positive_HIV related diseases, accidental needle prick injury.pdf [2] Senior notes: Maksim Medicine Notes.pdf (Section 9.8 HIV infections) [3] Past papers: 2022 Fourth Summative MCQ.pdf (Q19) [4] Medicine lecture slides: MBBS_SRH_2025.8.10.pdf (p16) [5] Past papers: 2020 Fourth Summative SAQ.pdf (Q10) [6] Past papers: 2024 Fourth Summative SAQ.pdf (Q12) [7] Senior notes: Block A - I am a hepatitis B carrier.pdf [8] Senior notes: Jerry's immunodeficiencies.pdf [9] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts.pdf [10] Senior notes: Gen Clerk Anaes + Microbiology Summary.pdf (TB in immunocompromised)
GC060 High White Cell Count
Leukocytosis is an elevation of the total white blood cell count above the normal range (typically >11,000/μL), indicating infection, inflammation, stress, or hematologic malignancy.
GC063 I Am Losing Weight And Sweating All The Time
A clinical presentation characterized by unintentional weight loss and excessive sweating, commonly suggesting hyperthyroidism, malignancy, chronic infection, or other hypermetabolic or systemic conditions requiring urgent evaluation.